Jan C Buckner Selected Research

Cisplatin (Platino)

8/2006	Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials.
5/2006	Ototoxicity of cisplatin plus standard radiation therapy vs. accelerated radiation therapy in glioblastoma patients.
2/2005	Phase II trial of carmustine, cisplatin, and oral etoposide chemotherapy before radiotherapy for grade 3 astrocytoma (anaplastic astrocytoma): results of North Central Cancer Treatment Group trial 98-72-51.
2/2002	Chemotherapy, irradiation, and surgery for function-preserving therapy of primary extremity soft tissue sarcomas: initial treatment with ifosfamide, mitomycin, doxorubicin, and cisplatin plus granulocyte macrophage-colony-stimulating factor.
1/2002	Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jan C Buckner Research Topics

Disease

64	Neoplasms (Cancer) 01/2024 - 01/2002
29	Glioma (Gliomas) 01/2024 - 06/2002
27	Glioblastoma (Glioblastoma Multiforme) 01/2024 - 12/2003
11	Astrocytoma (Pilocytic Astrocytoma) 07/2019 - 12/2003
10	Neoplasm Metastasis (Metastasis) 12/2022 - 02/2002
9	Brain Neoplasms (Brain Tumor) 12/2022 - 07/2003
8	Oligodendroglioma 07/2019 - 01/2003
4	Fatigue 01/2018 - 02/2006
3	Disease Progression 01/2018 - 05/2011
3	Diarrhea 06/2011 - 10/2006
3	Exanthema (Rash) 06/2011 - 12/2008
3	Vomiting 10/2006 - 02/2002
3	Sarcoma (Soft Tissue Sarcoma) 06/2002 - 01/2002
2	Thrombocytopenia (Thrombopenia) 01/2018 - 02/2002
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/2017 - 06/2010
2	Medulloblastoma 02/2014 - 01/2003
2	Hemangiopericytoma 05/2011 - 06/2003
2	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 06/2010 - 01/2002
2	Asthenia 06/2010 - 10/2006
2	Ototoxicity 08/2006 - 05/2006
1	Prostatic Neoplasms (Prostate Cancer) 01/2022
1	Hyperglycemia 01/2018
1	Wounds and Injuries (Trauma) 01/2018
1	Neutropenia 01/2018
1	Germ Cell and Embryonal Neoplasms (Germ Cell Tumor) 11/2017
1	Brain Diseases (Brain Disorder) 01/2017
1	Cognitive Dysfunction 07/2016
1	Hypoxia (Hypoxemia) 09/2013
1	Liver Diseases (Liver Disease) 10/2011
1	Cholangiocarcinoma 05/2011
1	Meningioma (Meningiomas) 05/2011
1	Infections 11/2010
1	Virus Diseases (Viral Diseases) 11/2010
1	Germinoma 08/2010

Drug/Important Bio-Agent (IBA)

16	Temozolomide (Temodar)FDA LinkGeneric 01/2022 - 05/2003
9	Vincristine (Oncovin)FDA LinkGeneric 10/2020 - 01/2003
9	Lomustine (CCNU)FDA Link 10/2020 - 01/2003
8	Procarbazine (Matulane)FDA Link 10/2020 - 01/2003
5	Biomarkers (Surrogate Marker)IBA 01/2019 - 03/2006
5	temsirolimus FDA Link 01/2018 - 08/2005
5	TOR Serine-Threonine KinasesIBA 01/2018 - 12/2004
5	Anticonvulsants (Antiepileptic Drugs)IBA 11/2015 - 10/2005
5	Carmustine (FIVB)FDA Link 08/2006 - 06/2002
5	Cisplatin (Platino)FDA LinkGeneric 08/2006 - 01/2002
4	Bevacizumab (Avastin)FDA Link 01/2022 - 09/2013
4	EnzymesIBA 11/2015 - 10/2005
4	ErbB Receptors (EGF Receptor)IBA 06/2011 - 07/2004
3	Imatinib Mesylate (Gleevec)FDA Link 07/2019 - 06/2010
3	Alkylating AgentsIBA 01/2019 - 05/2003
3	Irinotecan (Camptosar)FDA LinkGeneric 11/2015 - 05/2003
3	lipid-associated sialic acid (LASA)IBA 12/2014 - 02/2006
3	Doxorubicin (Adriamycin)FDA LinkGeneric 03/2011 - 01/2002
3	epidermal growth factor receptor VIIIIBA 12/2008 - 07/2004
2	VaccinesIBA 01/2024 - 01/2022
2	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 07/2019 - 01/2019
2	Vorinostat FDA Link 01/2018 - 04/2009
2	RNA (Ribonucleic Acid)IBA 01/2018 - 07/2004
2	Sorafenib (BAY 43-9006)FDA Link 01/2018 - 09/2013
2	Everolimus FDA Link 09/2015 - 10/2011
2	Etoposide (VP 16)FDA LinkGeneric 03/2011 - 02/2005
2	Ifosfamide FDA LinkGeneric 03/2011 - 02/2002
2	Transaminases (Aminotransferases)IBA 06/2010 - 10/2006
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 12/2008 - 07/2006
2	ParaffinIBA 10/2006 - 07/2004
2	Mitomycin (Mitomycin-C)FDA LinkGeneric 02/2002 - 01/2002
2	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 02/2002 - 01/2002
1	Carcinoembryonic AntigenIBA 01/2024
1	amsonic acid (DAS)IBA 01/2022
1	carotuximabIBA 01/2022
1	AntigensIBA 01/2022
1	src-Family KinasesIBA 11/2019
1	Dasatinib (BMS 354825)FDA Link 11/2019
1	Mitogen-Activated Protein KinasesIBA 01/2018
1	raf KinasesIBA 01/2018
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2018
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 01/2018
1	O-(6)-methylguanineIBA 10/2017
1	MethyltransferasesIBA 10/2017
1	O(6)-Methylguanine-DNA MethyltransferaseIBA 06/2016
1	Tumor Biomarkers (Tumor Markers)IBA 06/2015
1	Therapeutic UsesIBA 09/2013
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 09/2013
1	Gefitinib (Iressa)FDA Link 06/2011
1	Somatostatin Receptors (Somatostatin Receptor)IBA 05/2011
1	Octreotide (Sandostatin)FDA LinkGeneric 05/2011
1	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 05/2011
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 03/2011

Therapy/Procedure

42	Radiotherapy 12/2022 - 06/2002
30	Drug Therapy (Chemotherapy) 07/2019 - 01/2002
28	Therapeutics 12/2022 - 02/2002
2	Chemoradiotherapy 03/2014 - 11/2010
2	Adjuvant Chemotherapy 02/2014 - 11/2008
2	Drug Tapering 06/2010 - 10/2006
2	Craniotomy 05/2008 - 10/2005
1	Continuity of Patient Care 01/2022
1	Adjuvant Chemoradiotherapy 10/2020
1	Combination Drug Therapy (Combination Chemotherapy) 04/2016
1	Contraindications 05/2011
1	Antibiotic Prophylaxis 11/2010
1	Craniospinal Irradiation 08/2010